Tag: technology

Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific

by jezzabellemente, posted in Uncategorized

SINGAPORE, Nov 6 (Bernama-BUSINESS WIRE) — Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced the establishment of its co-headquarters in Singapore, marking a major milestone in the company’s global expansion and deepening its commitment to advancing eye health worldwide. Eyexora’s seed financing was led by ClavystBio, a global life sciences investor based in Singapore, and its initial programs have been in-licensed from the Singapore Eye Research Institute (SERI).

The new Singapore headquarters will serve as a gateway to Eyexora’s growing activities across the Asia-Pacific region, supporting clinical development, research collaborations, and regional partnerships. This expansion further strengthens Eyexora’s collaboration with the Singapore Eye Research Institute (SERI), a long-standing partner in ophthalmic innovation.

Eyexora’s Singapore operations will be instrumental in driving the company’s mission to develop transformative, accessible treatments for patients with vision-threatening diseases, while advancing scientific collaboration in one of the world’s most dynamic healthcare innovation hubs.

“Singapore has become a global center for ophthalmic research and innovation, and we are proud to deepen our presence here,” said Theresa Heah, M.D., M.B.A., Chief Executive Officer and Vice Chair of the Board, Eyexora. “This new co-headquarters positions Eyexora at the heart of Asia-Pacific’s biomedical ecosystem and strengthens our collaboration with SERI. Together, we are accelerating the development of breakthrough therapies that can improve vision and quality of life for patients around the world.”

“This milestone reflects our vision to build a truly global ophthalmic company,” said William J. Link, Ph.D, Chairman of the Board at Eyexora. “Singapore’s strong research infrastructure and commitment to innovation make it an ideal base for expanding Eyexora’s partnerships and advancing the next generation of eye care solutions.”

“Eyexora’s new co-headquarters are a testament to Singapore’s leadership in ophthalmology research and clinical delivery, and position as a global life sciences hub,” said Khoo Shih, Ph.D, CEO, ClavystBio. “At ClavystBio, we are excited to partner seasoned leaders like Theresa, William and their team to accelerate meaningful innovations and make global health impact.”

Last month Eyexora announced the launch of its second spoke company, Y.ora Vision, Inc., focused on developing next-generation ophthalmic medical devices for glaucoma. The company’s creation, complementing initial spoke company, Serenora Therapeutics, Inc., underscores Eyexora’s commitment to building a global ecosystem of specialized ventures that advance innovation across key therapeutic areas in ophthalmology.

Eyexora’s Singapore co-headquarters complements its U.S. base in New York, and will anchor the company’s Asia-Pacific operations, including clinical, scientific, and strategic functions, as it continues to grow its global footprint.

About Eyexora

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact. Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company and product launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter. For more information, visit www.eyexora.com.

About ClavystBio

ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Asia. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. For more information, please visit https://www.clavystbio.com/ and follow us on LinkedIn.

About Singapore Eye Research Institute (SERI)

Established in 1997, SERI is Singapore’s national research institute for ophthalmic and vision research. SERI’s mission is to conduct high-impact eye research that prevents blindness, low vision, and major eye diseases common to Singaporeans and Asians. Over the last decade, SERI has conducted landmark research projects that have led to tangible outcomes, patient benefits, and success stories. It has paved the way for significant improvements in how eye diseases are treated and prevented, not just for Singaporeans or Asians, but on a global scale.

At its inception, SERI saw a national remit in ophthalmic and vision research, and till today, SERI ensures that its facilities and resources are open to researchers across Singapore so that the greatest benefit may be obtained from what is a relatively small clinical ophthalmology catchment area in Singapore.

SERI has grown from a founding team of five in 1997 to a faculty of more than 253 staff, encompassing clinician scientists, scientists, research fellows, PhD students and support staff. This makes SERI one of the largest research institutes in Singapore, as well as the largest eye research institute in the Asia Pacific region. SERI has also over 255 adjunct faculties from various eye departments, biomedical institutes, and tertiary centres in Singapore. SERI has published an impressive array of 5,942 scientific papers and has secured external peer-reviewed competitive grants worth more than $473 million. As of December 2024, SERI’s faculty has been awarded with more than 1,425 national and international prizes and filed 188 patents.

As the research institute of the SNEC, and directly affiliated to the Yong Loo Lin School of Medicine, National University of Singapore, as well as the Duke-NUS Medical School, SERI undertakes vision research in collaboration with local clinical ophthalmic centres and biomedical research institutions, as well as major eye centres and research institutes throughout the world.

SERI ranks first globally in terms of eye publications per capita, far ahead of the US, UK, and Japan. With its impressive publication track record, SERI is comparable to renowned eye institutes, both regionally and internationally. Please see www.seri.com.sg.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20251104717799/en/

Contact

Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source : Eyexora

Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, and Drug Information

by jezzabellemente, posted in Uncategorized

PHILADELPHIA, Nov 5 (Bernama-GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today announced that it has granted a worldwide exclusive license, with the right to sublicense, to Scilex Holding Company (Nasdaq: SCLX), for Datavault AI’s proprietary AI-driven technology. This license is tailored for use within the biotech and biopharma industry, enabling Scilex to create and operate a Biotech Exchange platform. By leveraging Datavault AI’s advanced data platforms, Scilex can facilitate secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostic and therapeutic products, genetic information, and drug data. This agreement represents a major advancement in commercializing biotech innovations and builds directly on Datavault AI’s established expertise in high-performance computing and data-driven solutions.

Datavault AI believes this technology has the potential to extend into a Pharmaceutical Exchange platform, which could transform the pharmaceutical industry by enabling efficient, secure asset management and monetization.

Datavault AI estimates an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales.1 The Company also sees tokenization on such exchange platforms as an alternative for companies to secure non-dilutive funding for developing and commercializing diagnostic and therapeutic products.

This licensing agreement highlights Datavault AI’s robust intellectual property portfolio, including the key pending patent for “Platform and Method for Tokenizing DNA Data” (U.S. Patent Application No. 17/941,623), which establishes a secure framework for tokenizing and exchanging sensitive genetic information. The technology is bolstered by a comprehensive suite of issued and pending patents that power the Biotech Exchange, such as:

  • Issued: “Platform for Management of User Data” (U.S. Patent Nos. 11,593,515; 11,960,622; 12,100,025) and continuations, supporting secure data handling and monetization.
  • Issued: “Portfolio Driven Targeted Advertising Network, System, and Method” (U.S. Patent No. 11,315,150), facilitating data-driven targeting within exchange ecosystems.
  • Pending: “System and Method for Tokenized Minting, Authentication, and Utilization of Assets” (U.S. Patent Application No. 17/842,139), enabling biotech asset tokenization.
  • Pending: “Platform and Method for Tokenization of Corporate Data” (U.S. Patent Application No. 17/941,550), adaptable to biotech datasets.
  • Pending: “System and Method for Tokenized Licensing of Content” (U.S. Patent Application No. 17/842,328), for biotech IP licensing.
  • Pending: “System and Method for Tokenized Affiliate Marketing” (U.S. Patent Application No. 17/842,265), to foster biotech partnerships.
  • Pending: “System and Method for Funding a Virtual Location” (U.S. Patent Application No. 17/842,220), applicable to virtual biotech marketplaces.
  • Pending: “System and Method for Tokenized Event Management” (U.S. Patent Application No. 19/248,284), for biotech events and collaborations.
  • Pending: “System and Method for Registering Claims of Ownership Rights” (U.S. Patent Application No. 18/412,128), ensuring verifiable ownership in data trades.

These innovations collectively form the backbone of a secure, efficient Biotech Exchange, enabling tokenization, valuation, and trading of biotech data assets while upholding compliance and privacy.

Building on Datavault AI’s prior collaborations with Brookhaven National Laboratory, as announced in our June 17, 2025, press release, where we deployed AI-driven supercomputing for biofuel research to enhance fatty acid metabolism efficiency in Brassica napus (canola) using high-performance computational modeling, this license extends our proven AI and data monetization technologies into broader biotech applications. This follows our Sept. 16, 2024, announcement highlighting the Bioenergy Digital Twins Platform at the New York State Digital Summit, emphasizing real-time data synchronization and machine learning integration for bioenergy advancements.

Under the terms of the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and Sept. 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

Terms of License

Under the terms of the agreement, Datavault AI will receive a non-refundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

For more information on Datavault AI, visit www.dvlt.ai.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science Division leverages high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI’s cloud-based platform serves multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, Pennsylvania.

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), which is owned by Semnur (a majority-owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California. For more information, visit www.scilexholding.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, the Company’s license agreement with Scilex, the potential opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales, Datavault AI’s ability to support Scilex in leveraging its platforms for secure tokenization, trading, and monetization of biotech assets, the potential creation of a Pharmaceutical Exchange platform, expectations as to the opportunity to tokenize pharmaceutical drug sales and diagnostic sales, including the size of such opportunity, future opportunities for Datavault AI, its business strategies, long-term objectives, and commercialization plans, the current and prospective technologies, planned developments and potential approvals, as well as the potential for market acceptance and related market opportunities, and other statements that are not historical facts. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Datavault AI. These statements are subject to a number of risks and uncertainties regarding Datavault AI’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political, and business conditions; the ability of Datavault AI to achieve the benefits of the license agreement and other transactions contemplated with Scilex, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Scilex, including the license agreement; the risk that the transactions contemplated with Scilex disrupt current plans and operations; the ability of Datavault AI to develop and successfully market technologies; the ability of Datavault AI to grow and manage growth profitably and retain its key employees; the risk that the potential technologies that Datavault AI develops may not progress or receive required approvals within expected timelines or at all; risks relating to uncertainty regarding regulatory pathways; the risk that Datavault AI has overestimated the size of the target market, willingness to adopt new technologies, or partnerships; risks that prior results may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Scilex; the risk that Datavault AI will not benefit from a Pharmaceutical Exchange platform; and other risks and uncertainties indicated from time to time in Datavault AI’s filings with the SEC. There may be additional risks that Datavault AI presently does not know or that Datavault AI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Datavault AI’s expectations, plans, or forecasts of future events and views as of the date of this communication. Datavault AI anticipates that subsequent events and developments will cause such assessments to change. However, while Datavault AI may elect to update these forward-looking statements at some point in the future, Datavault AI specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Datavault AI’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. 

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Media Inquiries:
marketing@dvlt.ai
Website: www.dvlt.ai

1References
Sources for Pharmaceutical Drug Sales Data

The data for global pharmaceutical drug sales was primarily drawn from IQVIA Institute reports on global medicine spending, excluding COVID-19 vaccines and therapeutics for consistency. Here is the list of key sources referenced:

Sources for Diagnostic Sales Data

The data for global in vitro diagnostics (IVD) market sales was compiled from market research reports, with forecasts based on observed CAGRs (around 6.9% from 2020-2024). IQVIA provides qualitative insights, but quantitative figures were cross-referenced from other industry analyses for accuracy. Here is the list of key sources referenced:

SOURCE: Datavault AI Inc. 

DISCLAIMER: BERNAMA MREM are not accountable for any causes of website defacement, misuse, or illegal activities connected to cryptocurrency, blockchain, tokenisation, or bitcoin. This material should not be considered as guidance or an opinion, as it does not constitute financial or investment advice. Use this information at your own risk; we are not liable for any losses or damages caused by the republication of this article.

SOUNDHEALTH TO SHOWCASE AI-POWERED AIRWAY SCREENING APP AT WORLD SLEEP 2025

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Sept 19 (Bernama) — SoundHealth, a medical technology company specialising in artificial intelligence (AI) solutions for respiratory health, will debut its groundbreaking AI-powered mobile platform, Airway, at World Sleep 2025 in Singapore this September.

The smartphone-based tool is designed to screen for obstructive sleep apnoea and sleep-disordered breathing in both children and adults. The presentation will be delivered by a team of physicians and experts, including SoundHealth founder and chief executive officer, Paramesh Gopi.

“We believe the Airway app represents a significant breakthrough in accessible airway diagnostics. By putting a non-invasive, accurate screening tool directly into the hands of clinicians and patients, we are entering a new frontier in digital health,” he said in a statement.

Meanwhile, orthodontics and dental sleep medicine expert Dr Eric Phelps said the technology could transform early detection of airway and sleep-breathing disorders, while the app provides a safe, scalable and objective tool to screen patients across all ages, expanding access to diagnosis beyond traditional clinical settings.

Airway is described as the first mobile platform that enables accurate sinonasal and airway function assessment without relying on traditional imaging methods such as cone beam computed tomography (CBCT).

The application leverages a smartphone’s camera and microphone to provide a non-invasive and radiation-free solution for large-scale screening.

The system works by capturing 3D facial scans to extract craniofacial landmarks predictive of nasal dimensions, allowing for a virtual reconstruction of airway structures, and also analyses voice recordings to measure speech resonance in different positions, producing a “Voice Nasal Flow Index” sensitive to posture-related congestion and obstruction.

According to validation studies, the platform demonstrated 95 per cent accuracy when compared with clinical CT scans for key nasal airway parameters. It generates three main scores—upper airway susceptibility, lower airway resistance and the Voice Nasal Flow Index—combined into an overall “Airway Health Score”.

The app is designed for scalable use in schools, dental practices and sleep clinics, offering early detection of airway dysfunctions that may affect craniofacial development, orthodontic planning and sleep quality.

— BERNAMA

Mary Kay’s Iconic Pink Cadillac Goes Electric with the All-New OPTIQ

by jezzabellemente, posted in Uncategorized

“For decades, the Mary Kay pink Cadillac has symbolized accomplishment, aspiration, and the power of recognition,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “With the introduction of the all-electric OPTIQ, we’re honoring that iconic legacy while driving into a transformative future—one grounded in our commitment to sustainability and dedication to inspiring and celebrating the achievements of our independent sales force for generations to come.” (Photo Courtesy: Mary Kay Inc.)​

Next-Gen Career Car Drives Innovation, Sustainability, And Business Opportunity into the Future

DALLAS, July 25 (Bernama-BUSINESS WIRE) — Global cosmetics giant, Mary Kay Inc., today announced a major milestone in its legacy of empowerment: the transformation of its beloved pink Cadillac into a fully electric vehicle (EV). The pink Cadillac OPTIQ made its debut during Mary Kay’s annual Seminar, hosted for the first time in the vibrant city of Charlotte, North Carolina.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724749681/en/

The Cadillac OPTIQ is a significant step forward in Mary Kay’s commitment to innovation, environmental responsibility, and meeting expectations of the next generation of both Mary Kay independent sales force members and their customers. The transition from internal combustion to electric symbolizes more than just a vehicle upgrade, it marks a recharged vision for the future of the iconic beauty brand.

“For decades, the Mary Kay pink Cadillac has symbolized accomplishment, aspiration, and the power of recognition,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “With the introduction of the all-electric OPTIQ, we’re honoring that iconic legacy while driving into a transformative future—one grounded in our commitment to sustainability and dedication to inspiring and celebrating the achievements of our independent sales force for generations to come.”

“Our relationship with Mary Kay spans decades and is built on shared values of innovation, empowerment, and excellence,” said Ian Hucker, VP GM Envolve. “As the organization takes bold steps into the future with the transition to an electric vehicle, we are proud to stand beside them, supporting a vision that’s not only sustainable but also deeply inspiring. The pink Cadillac OPTIQ is an exciting step forward, bringing together the performance and luxury you expect from Cadillac with meaningful innovation and purpose-driven impact.”

About The Pink Cadillac OPTIQ:

  • OPTIQ retains the instantly recognizable pink pearl exterior, while introducing a sleek, modernized chassis with cutting-edge features. As part of Mary Kay’s commitment to sustainability, the vehicle showcases the company’s dedication to reducing its carbon footprint while continuing to inspire.
  • OPTIQ’s exceptional aerodynamic performance enables its EPA-estimated 302-mile driving range1. The revolutionary GM EV Battery Platform and drive units, along with the use of low rolling resistance tires, also play an important role in the impressive range of the vehicle.
  • A vented rear spoiler, diffusers, and other sculptural elements enhance aerodynamics at the rear of the vehicle without compromising the striking SUV vehicle design.
  • OPTIQ packages interior spaciousness and luxury into a comfortable suite. Illuminated décor and embellishments add to OPTIQ’s unique interior interpretation of Cadillac luxury, while the suite of in-vehicle technology includes features such as the 19-speaker AKG Audio System and Dolby Atmos, creating an intuitive experience.

Did You Know:

  • The iconic pink Cadillac was born in 1968 when Mary Kay Ash purchased a Cadillac Coupe De Ville from a Dallas dealership and promptly had it painted to match the pale pink Mary Kay® lip and eye palette. General Motors later named the color Mary Kay Pink Pearl, and the shade is exclusive to Mary Kay.
  • Mary Kay has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World2 by Euromonitor International for three consecutive years, in 2023, 2024, and again in 2025.

About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X.

    
1 GM-Estimated range based on development testing and/or analytical projection consistent with SAE J1634 revision 2017- MCT and subject to change prior to production. Actual range may vary based on several factors, including temperature, terrain, battery age, loading and how you use and maintain your vehicle. Visit www.cadillac.com for more information.
 
2 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20250724749681/en/

Contact

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

Source : Mary Kay Inc.

Spring Bio Solution Launches NCE Grid to decode Para IV Filing and First-to-File Opportunities

by jezzabellemente, posted in Uncategorized

SOMERSET, N.J., June 12 (Bernama-GLOBE NEWSWIRE) — Spring Bio Solution, a global leader in the comparator sourcing and clinical trial supplies, has launched NCE Grid, the world’s first free NCE-1 intelligence platform – built to decode, centralize, and visualize Para IV and NCE-1 opportunities in real-time.

Until now, tracking NCE exclusivity expirations and Paragraph IV filings has been a fragmented, manual, and cumbersome process, lacking a centralized solution. Regulatory updates are scattered across various portals, intelligence is buried in siloed databases, and timelines are tracked using spreadsheets. The result? Competitive blind spots, misaligned R&D, and a race already lost before it begins.

For generic pharmaceutical companies aiming to be the “first to file,” intelligence gaps, scattered data, and missed timelines can result in lost exclusivity and millions in revenue.

NCE Grid changes that.

NCE Grid is the world’s first free tool to integrate every critical data point, including molecule, innovator name, NCE-1 date, revenue, therapeutic usage, expected sales growth, and CAGR% into one intuitive platform. With real-time visualizations and actionable insights, NCE Grid empowers strategy, regulatory, and portfolio teams to identify, prioritize, and act on first-to-file opportunities with clarity and speed.

“We created NCE Grid because we saw too many companies struggle with fragmented insights and missed opportunities,” said Salim Shaikh, Founder and CEO of Spring Bio Solution. “In a race where timing is everything, our platform brings clarity, speed, and a competitive edge to decision-makers. When you think Para IV, think NCE Grid — Your trusted guide for strategic drug development.” 

To learn more, visithttps://ncegrid.springbiosolution.com/

About Spring Bio Solution

Spring Bio Solution partners with CROs, pharmaceutical companies, and research institutions worldwide, offering reliable solutions for comparator sourcing and clinical trial supplies. With offices and WDL (wholesale Drug Distribution License) facilities across the USA, EU, Singapore, and India, and a robust network of 400+ distribution partners and 30+ innovators, Spring Bio Solution ensures timely and compliant access to critical drug supplies.

Trusted by over 600 clients and maintaining a 99.9% success rate for sourcing comparator drugs/ RLDs/ innovator samples, the company offers industry-leading cold chain capabilities, ranging from -60°C to ambient temperatures. Through its partnership with LSPedia, Spring Bio Solution also ensures full DSCSA compliance and end-to-end traceability.

With experience supporting over 1,000 clinical trials and more than 12,000 bioequivalence studies, Spring Bio Solution empowers sponsors to de-risk operations and accelerate drug development with confidence.

For media inquiries, please contact:

Navdeep Trivedi
Vice President & Head, Digital Marketing
Spring Bio Solution
navdeep.trivedi@springbiosolution.com

SOURCE: Spring Bio Solution PTE.LTD